ImmunityBio (IBRX) shares surged over 10% today, continuing a rally that began in January, following the approval of its oncology drug Anktiva® by Macau’s regulatory body for certain bladder cancer treatments. This approval not only enhances ImmunityBio’s market presence but also paves the way for potential approvals in neighboring regions, including China, where the demand for innovative cancer therapies is growing.
The stock’s momentum is further supported by recent updates from the National Comprehensive Cancer Network (NCCN), which included Anktiva in its treatment guidelines for patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to standard BCG treatments. While the Macau market may be limited, this win signals a broader opportunity for ImmunityBio’s expansion across the Asia-Pacific, tapping into a burgeoning cancer immunotherapy market projected to reach $460 billion by 2035.
Investors should note that while ImmunityBio’s recent successes are promising, the biopharma sector remains highly competitive and volatile, making it a high-risk investment for those seeking stability.
Source: fool.com